Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus gemcitabine versus placebo plus gemcitabine in advanced/metastatic pancreatic cancer
2008-000974-18Phase 3Completed
- Sponsor
- AB Science
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic cancer (PC) comparing Masitinib + gemcitabine with Placebo + gemcitabine (2 arms). Primary endpoint: Overall survival. Started Feb 2009; status: completed.
02
Drugs
masitinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2008-000974-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000974-18.